litlas
ログインアカウント作成

Ronald M. Bukowski

1981–2016 年に発表

114
論文数
36,983
被引用数
90
h 指数
114
i10 指数

被引用数

Ronald M. Bukowski の年別被引用数1956 年: 被引用 2 件1982 年: 被引用 1 件1985 年: 被引用 1 件1986 年: 被引用 1 件1987 年: 被引用 7 件1988 年: 被引用 6 件1989 年: 被引用 3 件1990 年: 被引用 7 件1991 年: 被引用 8 件1992 年: 被引用 15 件1993 年: 被引用 19 件1994 年: 被引用 15 件1995 年: 被引用 27 件1996 年: 被引用 29 件1997 年: 被引用 36 件1998 年: 被引用 32 件1999 年: 被引用 86 件2000 年: 被引用 71 件2001 年: 被引用 82 件2002 年: 被引用 66 件2003 年: 被引用 69 件2004 年: 被引用 110 件2005 年: 被引用 117 件2006 年: 被引用 209 件2007 年: 被引用 351 件2008 年: 被引用 442 件2009 年: 被引用 528 件2010 年: 被引用 567 件2011 年: 被引用 465 件2012 年: 被引用 439 件2013 年: 被引用 387 件2014 年: 被引用 280 件2015 年: 被引用 291 件2016 年: 被引用 231 件2017 年: 被引用 185 件2018 年: 被引用 209 件2019 年: 被引用 638 件2020 年: 被引用 650 件2021 年: 被引用 508 件2022 年: 被引用 336 件2023 年: 被引用 263 件2024 年: 被引用 311 件2025 年: 被引用 104 件2026 年: 被引用 3 件1957〜1981 年は被引用が無いため表示していません1983〜1984 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,588 件、この内訳の 30.5%中国: 引用元論文 656 件、この内訳の 7.7%イタリア: 引用元論文 527 件、この内訳の 6.2%フランス: 引用元論文 515 件、この内訳の 6.1%イギリス: 引用元論文 502 件、この内訳の 5.9%ドイツ: 引用元論文 396 件、この内訳の 4.7%日本: 引用元論文 331 件、この内訳の 3.9%カナダ: 引用元論文 307 件、この内訳の 3.6%オランダ: 引用元論文 258 件、この内訳の 3%スペイン: 引用元論文 226 件、この内訳の 2.6%オーストラリア: 引用元論文 167 件、この内訳の 2%ベルギー: 引用元論文 156 件、この内訳の 1.8%
0%30.5%その他 22%

機関

分野

  • Medicine65.6%
  • Biochemistry, Genetics and Molecular Biology19.1%
  • Immunology and Microbiology11%
  • Materials Science0.8%
  • Neuroscience0.7%
  • Chemistry0.5%
  • その他2.3%

トピック

  • Renal cell carcinoma treatment10.7%
  • Cancer Immunotherapy and Biomarkers5.1%
  • Renal and related cancers3.2%
  • Angiogenesis and VEGF in Cancer3.1%
  • Immunotherapy and Immune Responses3.1%
  • Cancer Genomics and Diagnostics2.4%
  • その他72.4%

共著者

全論文

検索で開く
  1. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

    著者: Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan, Mark Warren, Ali Golshayan, Chakshu Sahi, Bernhard J. Eigl, Joseph D. Ruether, Tina Cheng, Scott North, Peter Venner, Jennifer J. Knox, Kim N., Christian Kollmannsberger, David F. McDermott, William Oh, Michael B. Atkins, Ronald M. Bukowski, Brian I. Rini, Toni K. Choueiri - Journal of Clinical Oncology 2009 被引用: 2,130

  2. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

    著者: Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Olivier Rixe, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Sindy T. Kim, Isan Chen, Paul Bycott, Charles M. Baum, Robert A. Figlin - New England Journal of Medicine 2007 被引用: 5,756

  3. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

    著者: Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Siebels, Sylvie Négrier, Christine Chevreau, E Solska, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sara M. Freeman, Brian Schwartz, Minghua Shan, Ronit Simantov, Ronald M. Bukowski - New England Journal of Medicine 2007 被引用: 4,784

  4. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    著者: Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Роберто Пили, Georg A. Bjarnason, Xavier García del Muro, Jeffrey A. Sosman, E Solska, George Wilding, John A. Thompson, Sindy T. Kim, Isan Chen, Xin Huang, Robert A. Figlin - Journal of Clinical Oncology 2009 被引用: 2,189

  5. Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

    著者: James H. Finke, Brian I. Rini, Joanna Ireland, Patricia Rayman, Amy L. Richmond, Ali Golshayan, Laura S. Wood, Paul Elson, J. Luz Tovar García, Robert Dreicer, Ronald M. Bukowski - Clinical Cancer Research 2008 被引用: 485

  6. Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

    著者: Toni K. Choueiri, Ulka N. Vaishampayan, Jonathan E. Rosenberg, Theodore F. Logan, Andrea Harzstark, Ronald M. Bukowski, Brian I. Rini, Sandy Srinivas, Mark N. Stein, Laurel M. Adams, Lone H. Ottesen, Kevin Laubscher, Laurie Sherman, David F. McDermott, Naomi B. Haas, Keith T. Flaherty, Robert W. Ross, Peter D. Eisenberg, Paul S. Meltzer, Maria J. Merino, Donald P. Bottaro, W. Marston Linehan, Ramaprasad Srinivasan - Journal of Clinical Oncology 2012 被引用: 458

  7. Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

    著者: Jennifer S. Ko, Arnold H. Zea, Brian I. Rini, Joanna Ireland, Paul Elson, Peter A. Cohen, Ali Golshayan, Patricia Rayman, Laura S. Wood, Jorge A. García, Robert Dreicer, Ronald M. Bukowski, James H. Finke - Clinical Cancer Research 2009 被引用: 852

  8. Sunitinib in Patients With Metastatic Renal Cell Carcinoma

    著者: Robert J. Motzer, Brian I. Rini, Ronald M. Bukowski, Brendan D. Curti, Daniel J. George, Gary R. Hudes, Bruce G. Redman, Kim Margolin, Jaime R. Merchan, George Wilding, Michelle S. Ginsberg, Jennifer Bacik, Sindy T. Kim, Charles M. Baum, M. Dror Michaelson - JAMA 2006 被引用: 1,228

  9. Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

    著者: Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Staehler, Sylvie Négrier, Christine Chevreau, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sibyl Anderson, Gloria Hofilena, Minghua Shan, Carol Peña, Chetan Lathia, Ronald M. Bukowski - Journal of Clinical Oncology 2009 被引用: 1,083

  10. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

    著者: Christopher G. Wood, Pramod K. Srivastava, Ronald M. Bukowski, Louis Lacombe, Gorelov Ai, S. Gorelov, Peter Mulders, Henryk Zieliński, Axel Hoos, Florentina Teofilovici, Leah Isakov, Robert C. Flanigan, Robert A. Figlin, Renu Gupta, Bernard Escudier - The Lancet 2008 被引用: 330

  11. Pazopanib

    著者: Ronald M. Bukowski, Uma Yasothan, Peter Kirkpatrick - Nature Reviews Drug Discovery 2009 被引用: 120

  12. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.

    著者: Robert J. Motzer, Ashok Rakhit, Lawrence H. Schwartz, Thomas Olencki, Terri Malone, Kate Sandstrom, R Nadeau, Hema Parmar, Ronald M. Bukowski - 1998 被引用: 231

  13. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma

    著者: Robert J. Motzer, Ronald M. Bukowski, Robert A. Figlin, Thomas E. Hutson, M. Dror Michaelson, Sindy T. Kim, Charles M. Baum, Michael W. Kattan - Cancer 2008 被引用: 217

  14. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

    著者: Olivier Rixe, Ronald M. Bukowski, M. Dror Michaelson, George Wilding, Gary R. Hudes, O. Bolte, Robert J. Motzer, Paul Bycott, Katherine Liau, James L. Freddo, Peter C. Trask, Sinil Kim, Brian I. Rini - The Lancet Oncology 2007 被引用: 436

  15. Multicenter, Randomized, Phase III Trial of CD8+ Tumor-Infiltrating Lymphocytes in Combination With Recombinant Interleukin-2 in Metastatic Renal Cell Carcinoma

    著者: Robert A. Figlin, John A. Thompson, Ronald M. Bukowski, Nicholas J. Vogelzang, Andrew C. Novick, Paul H. Lange, Gary D. Steinberg, Arie S. Belldegrun - Journal of Clinical Oncology 1999 被引用: 213

  16. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

    著者: Brian I. Rini, David F. McDermott, Hans J. Hammers, William Bro, Ronald M. Bukowski, Bernard Faba, Jo Faba, Robert A. Figlin, Thomas E. Hutson, Eric Jonasch, Richard W. Joseph, Bradley C. Leibovich, Thomas Olencki, Allan J. Pantuck, David I. Quinn, Virginia Seery, Martin H. Voss, Christopher G. Wood, Laura S. Wood, Michael B. Atkins - Journal for ImmunoTherapy of Cancer 2016 被引用: 122

  17. The Role of Inflammation in Kidney Cancer

    著者: Antonio Roma de Vivar Chevez, James H. Finke, Ronald M. Bukowski - Advances in experimental medicine and biology 2014 被引用: 108

  18. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

    著者: Martin Gore, Cezary Szczylik, Camillo Porta, Sergio Bracarda, Georg A. Bjarnason, Stéphane Oudard, Subramanian Hariharan, Se‐Hoon Lee, John B.A.G. Haanen, Daniel Castellano, Eduard Vrdoljak, Patrick Schöffski, Paul N. Mainwaring, Alejandra Nieto, Jinyu Yuan, Ronald M. Bukowski - The Lancet Oncology 2009 被引用: 591

  19. Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

    著者: Tarek Mekhail, Rony M. Abou-Jawde, Gabriel BouMerhi, Sareena Malhi, Laura S. Wood, Paul Elson, Ronald M. Bukowski - Journal of Clinical Oncology 2005 被引用: 571

  20. Targeted Therapy for Metastatic Renal Cell Carcinoma

    著者: Robert J. Motzer, Ronald M. Bukowski - Journal of Clinical Oncology 2006 被引用: 457

  21. Randomized Multicenter Phase II Trial of Subcutaneous Recombinant Human Interleukin-12 Versus Interferon-α2a for Patients with Advanced Renal Cell Carcinoma

    著者: Robert J. Motzer, Ashok Rakhit, John A. Thompson, John Nemunaitis, Barbara A. Murphy, Julie A. Ellerhorst, Lawrence H. Schwartz, William J. Berg, Ronald M. Bukowski - Journal of Interferon & Cytokine Research 2001 被引用: 118

  22. Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

    著者: Bernard Escudier, Cezary Szczylik, Thomas E. Hutson, Tomasz Demkow, Michael Staehler, Frédéric Rolland, Sylvie Négrier, Nicole Laferriere, Urban Scheuring, David Cella, Sonalee Shah, Ronald M. Bukowski - Journal of Clinical Oncology 2009 被引用: 491

  23. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

    著者: Eric Van Cutsem, Paulo M. Hoff, Peter Harper, Ronald M. Bukowski, David Cunningham, P Dufour, Ullrich Graeven, J Lokich, Stefan Madajewicz, Jean A. Maroun, John L. Marshall, Edith P. Mitchell, G. Pérez-Manga, P. Rougier, Wolff Schmiegel, Juergen Schöelmerich, Alberto Sobrero, Richard L. Schilsky - British Journal of Cancer 2004 被引用: 398

  24. A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

    著者: Kwok-K. Wong, Paula M. Fracasso, Ronald M. Bukowski, Thomas J. Lynch, Pamela N. Münster, Geoffrey I. Shapiro, Pasi A. Jänne, Joseph P. Eder, Michael Naughton, Matthew J. Ellis, Suzanne F. Jones, Tarek Mekhail, Charles Zacharchuk, Jennifer Vermette, Richat Abbas, Susan Quinn, Christine Powell, Howard A. Burris - Clinical Cancer Research 2009 被引用: 303